The secretome of skin cancer cells activates the mTOR/MYC pathway in healthy keratinocytes and induces tumorigenic properties.


Journal

Biochimica et biophysica acta. Molecular cell research
ISSN: 1879-2596
Titre abrégé: Biochim Biophys Acta Mol Cell Res
Pays: Netherlands
ID NLM: 101731731

Informations de publication

Date de publication:
08 2020
Historique:
received: 28 11 2019
revised: 20 03 2020
accepted: 07 04 2020
pubmed: 14 4 2020
medline: 27 10 2020
entrez: 14 4 2020
Statut: ppublish

Résumé

Cutaneous squamous cell carcinoma (cSCC) is the most prominent tumor of non-melanoma skin cancers and the most aggressive tumor among keratinocyte carcinoma of the skin, showing a high potential for local invasion and metastasis. The cSCC incidences increased dramatically in recent years and the disease occurs more commonly than any other malignancy. The secretome of cancer cells is currently the focus of many studies in order to identify new marker proteins for different types of cancer and to investigate its influence on the tumor microenvironment. In our study we evaluated whether the secretome of cSCC cells has an impact on keratinocytes, the surrounding tissue cells of cSCC. Therefore, we analyzed and compared the secretome of human A431 cancer cells and of HaCaT keratinocytes by mass spectrometry. In a second experiment, keratinocytes were exposed to the secretome of A431 cells and vice versa and the transcriptome was analyzed by next-generation sequencing. HaCaT cells incubated with A431 conditioned medium revealed a significantly activated mammalian target of rapamycin pathway with a concomitant increase in proliferation and migration. In conclusion, our data demonstrate the impact of the secretome of cancer cells on the transcription machinery of the cells surrounding the tumor, leading to a tumorigenic cell fate.

Identifiants

pubmed: 32283126
pii: S0167-4889(20)30075-6
doi: 10.1016/j.bbamcr.2020.118717
pii:
doi:

Substances chimiques

MYC protein, human 0
Proteome 0
Proto-Oncogene Proteins c-myc 0
MTOR protein, human EC 2.7.1.1
TOR Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

118717

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Christine Hoesl (C)

Institute of Molecular Animal Breeding and Biotechnology, Gene Center, LMU, München, Germany.

Enrica Zanuttigh (E)

Institute of Molecular Animal Breeding and Biotechnology, Gene Center, LMU, München, Germany.

Thomas Fröhlich (T)

Laboratory for Functional Genome Analysis LAFUGA, Gene Center, LMU, München, Germany.

Julia Philippou-Massier (J)

Laboratory for Functional Genome Analysis LAFUGA, Gene Center, LMU, München, Germany.

Stefan Krebs (S)

Laboratory for Functional Genome Analysis LAFUGA, Gene Center, LMU, München, Germany.

Helmut Blum (H)

Laboratory for Functional Genome Analysis LAFUGA, Gene Center, LMU, München, Germany.

Maik Dahlhoff (M)

Institute of Molecular Animal Breeding and Biotechnology, Gene Center, LMU, München, Germany. Electronic address: dahlhoff@lmb.uni-muenchen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH